ADTX - Aditxt, Inc.
vs
Region: US
Website: aditxt.com
Employees: 60
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Aditxt, Inc. develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (N
Read moreAppili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
RICHMOND, Va., April 02, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the ur
Read moreUpcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
MOUNTAIN VIEW, Calif., March 28, 2025--Aditxt, Inc. (NASDAQ: ADTX), ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. ("Pearsanta"). The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and other illnesses. The discussio
Read more